Cargando…
Treating refractory leukemias in childhood, role of clofarabine
Approximately 4000 children and adolescents under the age of 20 years develop acute leukemia per year in the US. Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. Despite impressive improvements in outcome, relapsed ALL is the fourth most common pediatric malignancy. Therapy fo...
Autores principales: | Harned, Theresa M, Gaynon, Paul S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504075/ https://www.ncbi.nlm.nih.gov/pubmed/18728851 |
Ejemplares similares
-
Use of clofarabine for acute childhood leukemia
por: Pession, A, et al.
Publicado: (2010) -
Efficacy of Low Dose Clofarabine in Refractory Precursor T- Acute Lymphoblastic Leukemia
por: Choi, Jaehyuk, et al.
Publicado: (2007) -
Clofarabine monotherapy in two patients with refractory Langerhans cell histiocytosis
por: Irie, Masahiro, et al.
Publicado: (2021) -
A Real-World Study on Clofarabine and Cytarabine Combination in Patients with Relapsed/Refractory Acute Myeloid Leukemia
por: Crobu, Valeria, et al.
Publicado: (2019) -
Clofarabine Experience in Children with Multi-Relapsed Acute Leukemia
por: Karakaş, Zeynep, et al.
Publicado: (2014)